The adenoviral oncogene E1A-13S interacts with a specific isoform of the tumor suppressor PML to enhance viral transcription

Journal of Virology

Volumn 87, Issue 2, 2013, Pages 965-977

  Berscheminski, Julia ^a   Groitl, Peter ^a   Dobner, Thomas ^a   Wimmer, Peter ^a   Schreiner, Sabrina ^a  

^a LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

E1A PROTEIN; E1B PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN;

ADENOVIRUS INFECTION; ARTICLE; CELL NUCLEUS INCLUSION BODY; CONTROLLED STUDY; DOWN REGULATION; E1A 13S GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE INTERACTION; GENE LOCATION; GENE MAPPING; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROGENY; PROTEIN DNA INTERACTION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; SITE DIRECTED MUTAGENESIS; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; VIRUS ONCOGENE; VIRUS TRANSCRIPTION;

ADENOVIRUS E1A PROTEINS; ADENOVIRUSES, HUMAN; BINDING SITES; DNA MUTATIONAL ANALYSIS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOPRECIPITATION; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN ISOFORMS; SEQUENCE DELETION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

DNA VIRUSES;

EID: 84871958784     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02023-12     Document Type: Article

References (106)

1. Flint J, Shenk T. 1989. Adenovirus E1A protein paradigm viral transactivator. Annu. Rev. Genet. 23:141-161.
2. Chow LT, Broker TR, Lewis JB. 1979. Complex splicing patterns of RNAs from the early regions of adenovirus-2. J. Mol. Biol. 134:265-303.
3. Perricaudet M, Akusjarvi G, Virtanen A, Pettersson U. 1979. Structure of two spliced mRNAs from the transforming region of human subgroup C adenoviruses. Nature 281:694-696.
4. Hiebert SW, Blake M, Azizkhan J, Nevins JR. 1991. Role of E2F transcription factor in E1A-mediated trans activation of cellular genes. J. Virol. 65:3547-3552.
5. Kovesdi I, Reichel R, Nevins JR. 1986. Identification of a cellular transcription factor involved in E1A trans-activation. Cell 45:219-228.
6. Liu F, Green MR. 1990. A specific member of the ATF transcription factor family can mediate transcription activation by the adenovirus E1a protein. Cell 61:1217-1224.
7. Nevins JR. 1990. Adenovirus E1A-dependent trans-activation of transcription. Semin. Cancer Biol. 1:59-68.
8. Stevens JL, Cantin GT, Wang G, Shevchenko A, Berk AJ. 2002. Transcription control by E1A and MAP kinase pathway via Sur2 mediator subunit. Science 296:755-758.
9. Ascoli CA, Maul GG. 1991. Identification of a novel nuclear domain. J. Cell Biol. 112:785-795.
10. Chang KS, Stass SA, Chu DT, Deaven LL, Trujillo JM, Freireich EJ. 1992. Characterization of a fusion cDNA (RARA/myl) transcribed from the t(15;17) translocation breakpoint in acute promyelocytic leukemia. Mol. Cell. Biol. 12:800-810.
11. de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. 1991. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66:675-684.
12. Dyck JA, Maul GG, Miller WH, Jr, Chen JD, Kakizuka A, Evans RM. 1994. A novel macromolecular structure is a target of the promyelocyteretinoic acid receptor oncoprotein. Cell 76:333-343.
13. Goddard AD, Borrow J, Solomon E. 1992. A previously uncharacterized gene, PML, is fused to the retinoic acid receptor alpha gene in acute promyelocytic leukaemia. Leukemia. 6(Suppl 3):117S-119S.
14. Kakizuka A, Miller WH, Jr, Umesono K, Warrell RP, Jr, Frankel SR, Murty VV, Dmitrovsky E, Evans RM. 1991. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66:663-674.
15. Kastner P, Perez A, Lutz Y, Rochette-Egly C, Gaub MP, Durand B, Lanotte M, Berger R, Chambon P. 1992. Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins. EMBO J. 11:629-642.
16. Koken MH, Puvion-Dutilleul F, Guillemin MC, Viron A, Linares-Cruz G, Stuurman N, de Jong L, Szostecki C, Calvo F, Chomienne C. 1994. The t(15;17) translocation alters a nuclear body in a retinoic acidreversible fashion. EMBO J. 13:1073-1083.
17. Melnick A, Fruchtman S, Zelent A, Liu M, Huang Q, Boczkowska B, Calasanz M, Fernandez A, Licht JD, Najfeld V. 1999. Identification of novel chromosomal rearrangements in acute myelogenous leukemia involving loci on chromosome 2p23, 15q22 and 17q21. Leukemia 13: 1534-1538.
18. Melnick A, Licht JD. 1999. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93:3167-3215.
19. Pandolfi PP, Alcalay M, Fagioli M, Zangrilli D, Mencarelli A, Diverio D, Biondi A, Lo Coco F, Rambaldi A, Grignani F. 1992. Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia. EMBO J. 11:1397-1407.
20. Weis K, Rambaud S, Lavau C, Jansen J, Carvalho T, Carmo-Fonseca M, Lamond A, Dejean A. 1994. Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell 76:345-356.
21. Jensen K, Shiels C, Freemont PS. 2001. PML protein isoforms and the RBCC/TRIM motif. Oncogene 20:7223-7233.
22. Bernardi R, Pandolfi PP. 2007. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat. Rev. Mol. Cell Biol. 8:1006-1016.
23. Ishov AM, Sotnikov AG, Negorev D, Vladimirova OV, Neff N, Kamitani T, Yeh ET, Strauss JF III, Maul GG. 1999. PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J. Cell Biol. 147:221-234.
24. Shen TH, Lin HK, Scaglioni PP, Yung TM, Pandolfi PP. 2006. The mechanisms of PML-nuclear body formation. Mol. Cell 24:331-339.
25. Negorev D, Maul GG. 2001. Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot. Oncogene 20:7234-7242.
26. Zhong S, Muller S, Ronchetti S, Freemont PS, Dejean A, Pandolfi PP. 2000. Role of SUMO-1-modified PML in nuclear body formation. Blood 95:2748-2752.
27. Seeler JS, Dejean A. 2003. Nuclear and unclear functions of SUMO. Nat. Rev. Mol. Cell Biol. 4:690-699.
28. Lallemand-Breitenbach V, Zhu J, Puvion F, Koken M, Honore N, Doubeikovsky A, Duprez E, Pandolfi PP, Puvion E, Freemont P, de The H. 2001. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3- induced PML or PML/retinoic acid receptor alpha degradation. J. Exp. Med. 193:1361-1371.
29. Li H, Leo C, Zhu J, Wu X, O'Neil J, Park EJ, Chen JD. 2000. Sequestration and inhibition of Daxx-mediated transcriptional repression by PML. Mol. Cell. Biol. 20:1784-1796.
30. Zhong S, Salomoni P, Pandolfi PP. 2000. The transcriptional role of PML and the nuclear body. Nat. Cell Biol. 2:E85-E90.
31. Bischof O, Kirsh O, Pearson M, Itahana K, Pelicci PG, Dejean A. 2002. Deconstructing PML-induced premature senescence. EMBO J. 21: 3358-3369.
32. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW. 2000. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev. 14:2015-2027.
33. Langley E, Pearson M, Faretta M, Bauer UM, Frye RA, Minucci S, Pelicci PG, Kouzarides T. 2002. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 21:2383-2396.
34. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, Higashimoto Y, Appella E, Minucci S, Pandolfi PP, Pelicci PG. 2000. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406:207-210.
35. Salomoni P, Ferguson BJ, Wyllie AH, Rich T. 2008. New insights into the role of PML in tumour suppression. Cell Res. 18:622-640. 36. Salomoni P, Pandolfi PP. 2002. The role of PML in tumor suppression. Cell 108:165-170.
36. Salomoni P, Pandolfi PP. 2002. The role of PML in tumor suppression. Cell 108:165-170.
37. Bischof O, Kim SH, Irving J, Beresten S, Ellis NA, Campisi J. 2001. Regulation and localization of the Bloom syndrome protein in response to DNA damage. J. Cell Biol. 153:367-380.
38. Carbone R, Pearson M, Minucci S, Pelicci PG. 2002. PML NBs associate with the hMre11 complex and p53 at sites of irradiation induced DNA damage. Oncogene 21:1633-1640.
39. Hofmann TG, Will H. 2003. Body language: the function of PML nuclear bodies in apoptosis regulation. Cell Death Differ. 10:1290-1299. 40. Takahashi Y, Lallemand-Breitenbach V, Zhu J, de The H. 2004. PML nuclear bodies and apoptosis. Oncogene 23:2819-2824.
40. Takahashi Y, Lallemand-Breitenbach V, Zhu J, de The H. 2004. PML nuclear bodies and apoptosis. Oncogene 23:2819-2824.
41. Torok D, Ching RW, Bazett-Jones DP. 2009. PML nuclear bodies as sites of epigenetic regulation. Front. Biosci. 14:1325-1336.
42. Ahn JH, Brignole EJ III, Hayward GS. 1998. Disruption of PML subnuclear domains by the acidic IE1 protein of human cytomegalovirus is mediated through interaction with PML and may modulate a RING finger- dependent cryptic transactivator function of PML. Mol. Cell. Biol. 18:4899-4913.
43. Guiochon-Mantel A, Savouret JF, Quignon F, Delabre K, Milgrom E, De The H. 1995. Effect of PML and PML-RAR on the transactivation properties and subcellular distribution of steroid hormone receptors. Mol. Endocrinol. 9:1791-1803.
44. Vallian S, Gaken JA, Gingold EB, Kouzarides T, Chang KS, Farzaneh F. 1998. Modulation of Fos-mediated AP-1 transcription by the promyelocytic leukemia protein. Oncogene 16:2843-2853.
45. Alcalay M, Tomassoni L, Colombo E, Stoldt S, Grignani F, Fagioli M, Szekely L, Helin K, Pelicci PG. 1998. The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein. Mol. Cell. Biol. 18:1084-1093.
46. Vallian S, Chin KV, Chang KS. 1998. The promyelocytic leukemia protein interacts with Sp1 and inhibits its transactivation of the epidermal growth factor receptor promoter. Mol. Cell. Biol. 18:7147-7156.
47. Doucas V, Tini M, Egan DA, Evans RM. 1999. Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling. Proc. Natl. Acad. Sci. U. S. A. 96:2627-2632.
48. Zhong S, Delva L, Rachez C, Cenciarelli C, Gandini D, Zhang H, Kalantry S, Freedman LP, Pandolfi PP. 1999. A RA-dependent, tumour- growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins. Nat. Genet. 23:287-295.
49. Everett RD. 2001. DNA viruses and viral proteins that interact with PML nuclear bodies. Oncogene 20:7266-7273.
50. Everett RD, Chelbi-Alix MK. 2007. PML and PML nuclear bodies: implications in antiviral defence. Biochimie 89:819-830.
51. Tavalai N, Stamminger T. 2008. New insights into the role of the subnuclear structure ND10 for viral infection. Biochim. Biophys. Acta 1783: 2207-2221.
52. Doucas V, Ishov AM, Romo A, Juguilon H, Weitzman MD, Evans RM, Maul GG. 1996. Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure. Genes Dev. 10:196-207.
53. Ishov AM, Maul GG. 1996. The periphery of nuclear domain 10 (ND10) as site of DNA virus deposition. J. Cell Biol. 134:815-826.
54. Jul-Larsen A, Visted T, Karlsen BO, Rinaldo CH, Bjerkvig R, Lonning PE, Boe SO. 2004. PML-nuclear bodies accumulate DNA in response to polyomavirus BK and simian virus 40 replication. Exp. Cell Res. 298:58-73.
55. Maul GG. 1998. Nuclear domain 10, the site of DNA virus transcription and replication. Bioessays 20:660-667.
56. Maul GG, Ishov AM, Everett RD. 1996. Nuclear domain 10 as preexisting potential replication start sites of herpes simplex virus type-1. Virology 217:67-75.
57. Sourvinos G, Everett RD. 2002. Visualization of parental HSV-1 genomes and replication compartments in association with ND10 in live infected cells. EMBO J. 21:4989-4997.
58. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, Guguen-Guillouzo C. 2002. Infection of a human hepatoma cell line by hepatitis B virus. Proc. Natl. Acad. Sci. U. S. A. 99:15655-15660.
59. Cuchet D, Sykes A, Nicolas A, Orr A, Murray J, Sirma H, Heeren J, Bartelt A, Everett RD. PML isoforms I and II participate in PMLdependent restriction of HSV-1 replication. J. Cell Sci. 124:280-291.
60. Mitsudomi T, Oyama T, Gazdar AF, Minna JD, Okabayashi K, Shirakusa T. 1992. Mutations of ras and p53 genes in human non-small cell lung cancer cell lines and their clinical significance. Nihon Geka Gakkai Zasshi 93:944-947.
61. Wang ZG, Delva L, Gaboli M, Rivi R, Giorgio M, Cordon-Cardo C, Grosveld F, Pandolfi PP. 1998. Role of PML in cell growth and the retinoic acid pathway. Science 279:1547-1551.
62. Muller D, Schreiner S, Schmid M, Groitl P, Winkler M, Dobner T. 2012. Functional cooperation between human adenovirus type 5 early region 4, open reading frame 6 protein, and cellular homeobox protein HoxB7. J. Virol. 86:8296-8308.
63. Groitl P, Dobner T. 2007. Construction of adenovirus type 5 early region 1 and 4 virus mutants. Methods Mol. Med. 130:29-39.
64. Winberg G, Shenk T. 1984. Dissection of overlapping functions within the adenovirus type 5 E1A gene. EMBO J. 3:1907-1912.
65. Forrester NA, Patel RN, Speiseder T, Groitl P, Sedgwick GG, Shimwell NJ, Seed RI, Catnaigh PO, McCabe CJ, Stewart GS, Dobner T, Grand RJ, Martin A, Turnell AS. 2012. Adenovirus E4orf3 targets transcriptional intermediary factor 1gamma for proteasome-dependent degra.dation during infection. J. Virol. 86:3167-3179.
66. Kindsmuller K, Schreiner S, Leinenkugel F, Groitl P, Kremmer E, Dobner T. 2009. A 49-kilodalton isoform of the adenovirus type 5 early region 1B 55-kilodalton protein is sufficient to support virus replication. J. Virol. 83:9045-9056.
67. Schreiner S, Martinez R, Groitl P, Rayne F, Vaillant R, Wimmer P, Bossis G, Sternsdorf T, Ruszsics Z, Dobner T, Wodrich H. 2012. Transcriptional activation of the adenoviral genome is mediated by capsid protein. PLoS Pathog. 8 (2):e1002549. doi:10.1371/journal. ppat.1002549.
68. Harlow E, Franza BR, Jr, Schley C. 1985. Monoclonal antibodies specific for adenovirus early region 1A proteins: extensive heterogeneity in early region 1A products. J. Virol. 55:533-546.
69. Reich NC, Sarnow P, Duprey E, Levine AJ. 1983. Monoclonal antibodies which recognize native and denatured forms of the adenovirus DNAbinding protein. Virology 128:480-484.
70. Wimmer P, Blanchette P, Schreiner S, Ching W, Groitl P, Berscheminski J, Branton PE, Will H, Dobner T. 21 May 2012. Cross-talk between phosphorylation and SUMOylation regulates transforming ac-tivities of an adenoviral oncoprotein. Oncogene, in press. doi:10.1038/ onc.2012.187.
71. Endter C, Hartl B, Spruss T, Hauber J, Dobner T. 2005. Blockage of CRM1-dependent nuclear export of the adenovirus type 5 early region 1B 55-kDa protein augments oncogenic transformation of primary rat cells. Oncogene 24:55-64.
72. Carvalho T, Seeler JS, Ohman K, Jordan P, Pettersson U, Akusjarvi G, Carmo-Fonseca M, Dejean A. 1995. Targeting of adenovirus E1A and E4-ORF3 proteins to nuclear matrix-associated PML bodies. J. Cell Biol. 131:45-56.
73. Shenk T, Flint J. 1991. Transcriptional and transforming activities of the adenovirus E1A proteins. Adv. Cancer Res. 57:47-85.
74. Eskiw CH, Dellaire G, Mymryk JS, Bazett-Jones DP. 2003. Size, position and dynamic behavior of PML nuclear bodies following cell stress as a paradigm for supramolecular trafficking and assembly. J. Cell Sci. 116: 4455-4466.
75. Nardozza TA, Quigley MM, Getzenberg RH. 1996. Association of transcription factors with the nuclear matrix. J. Cell. Biochem. 61:467-477.
76. Hoppe A, Beech SJ, Dimmock J, Leppard KN. 2006. Interaction of the adenovirus type 5 E4 Orf3 protein with promyelocytic leukemia protein isoform II is required for ND10 disruption. J. Virol. 80:3042-3049.
77. Leppard KN, Emmott E, Cortese MS, Rich T. 2009. Adenovirus type 5 E4 Orf3 protein targets promyelocytic leukaemia (PML) protein nuclear domains for disruption via a sequence inPMLisoform II that is predicted as a protein interaction site by bioinformatic analysis. J. Gen. Virol. 90: 95-104.
78. Puvion-Dutilleul F, Chelbi-Alix MK, Koken M, Quignon F, Puvion E, de The H. 1995. Adenovirus infection induces rearrangements in the intranuclear distribution of the nuclear body-associated PML protein. Exp. Cell Res. 218:9-16.
79. Leppard KN, Everett RD. 1999. The adenovirus type 5 E1b 55K and E4 Orf3 proteins associate in infected cells and affect ND10 components. J. Gen. Virol. 80:997-1008.
80. Schreiner S, Wimmer P, Sirma H, Everett RD, Blanchette P, Groitl P, Dobner T. 2010. Proteasome-dependent degradation of Daxx by the viral E1B-55K protein in human adenovirus-infected cells. J. Virol. 84: 7029-7038.
81. Sieber T, Dobner T. 2007. Adenovirus type 5 early region 1B 156R protein promotes cell transformation independently of repression of p53-stimulated transcription. J. Virol. 81:95-105.
82. Wimmer P, Schreiner S, Everett RD, Sirma H, Groitl P, Dobner T. 2010. SUMO modification of E1B-55K oncoprotein regulates isoformspecific binding to the tumour suppressor protein PML. Oncogene 29: 5511-5522.
83. Zhao LY, Colosimo AL, Liu Y, Wan Y, Liao D. 2003. Adenovirus E1B 55-kilodalton oncoprotein binds to Daxx and eliminates enhancement of p53-dependent transcription by Daxx. J. Virol. 77:11809-11821.
84. Liu F, Green MR. 1994. Promoter targeting by adenovirus E1a through interaction with different cellular DNA-binding domains. Nature 368: 520-525.
85. Pelka P, Ablack JN, Fonseca GJ, Yousef AF, Mymryk JS. 2008. Intrinsic structural disorder in adenovirus E1A: a viral molecular hub linking multiple diverse processes. J. Virol. 82:7252-7263.
86. Webster LC, Ricciardi RP. 1991. trans-dominant mutants of E1A provide genetic evidence that the zinc finger of the trans-activating domain binds a transcription factor. Mol. Cell. Biol. 11:4287-4296.
87. Regad T, Chelbi-Alix MK. 2001. Role and fate of PML nuclear bodies in response to interferon and viral infections. Oncogene 20:7274-7286.
88. Pelka P, Ablack JN, Torchia J, Turnell AS, Grand RJ, Mymryk JS. 2009. Transcriptional control by adenovirus E1A conserved region 3 via p300/CBP. Nucleic Acids Res. 37:1095-1106.
89. Goodman RH, Smolik S. 2000. CBP/p300 in cell growth, transformation, and development. Genes Dev. 14:1553-1577.
90. LaMorte VJ, Dyck JA, Ochs RL, Evans RM. 1998. Localization of nascent RNA and CREB binding protein with the PML-containing nuclear body. Proc. Natl. Acad. Sci. U. S. A. 95:4991-4996.
91. von Mikecz A, Zhang S, Montminy M, Tan EM, Hemmerich P. 2000. CREB-binding protein (CBP)/p300 and RNA polymerase II colocalize in transcriptionally active domains in the nucleus. J. Cell Biol. 150:265-273.
92. Ullman AJ, Hearing P. 2008. Cellular proteins PML and Daxx mediate an innate antiviral defense antagonized by the adenovirus E4 ORF3 protein. J. Virol. 82:7325-7335.
93. Duprez E, Saurin AJ, Desterro JM, Lallemand-Breitenbach V, Howe K, Boddy MN, Solomon E, de The H, Hay RT, Freemont PS. 1999. SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation. J. Cell Sci. 112:381-393.
94. Geoffroy MC, Chelbi-Alix MK. 2011. Role of promyelocytic leukemia protein in host antiviral defense. J. Interferon Cytokine Res. 31:145-158.
95. Lavau C, Marchio A, Fagioli M, Jansen J, Falini B, Lebon P, Grosveld F, Pandolfi PP, Pelicci PG, Dejean A. 1995. The acute promyelocytic leukaemia-associated PML gene is induced by interferon. Oncogene 11: 871-876.
96. Day PM, Baker CC, Lowy DR, Schiller JT. 2004. Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression. Proc. Natl. Acad. Sci. U. S. A. 101:14252-14257.
97. Ishov AM, Stenberg RM, Maul GG. 1997. Human cytomegalovirus immediate early interaction with host nuclear structures: definition of an immediate transcript environment. J. Cell Biol. 138:5-16.
98. Lilley CE, Carson CT, Muotri AR, Gage FH, Weitzman MD. 2005. DNA repair proteins affect the lifecycle of herpes simplex virus 1. Proc. Natl. Acad. Sci. U. S. A. 102:5844-5849.
99. Weitzman MD, Carson CT, Schwartz RA, Lilley CE. 2004. Interactions of viruses with the cellular DNA repair machinery. DNA Repair (Amst.) 3:1165-1173.
100. Wilkinson DE, Weller SK. 2004. Recruitment of cellular recombination and repair proteins to sites of herpes simplex virus type 1 DNA replication is dependent on the composition of viral proteins within prereplicative sites and correlates with the induction of the DNA damage response. J. Virol. 78:4783-4796.
101. Tang Q, Bell P, Tegtmeyer P, Maul GG. 2000. Replication but not transcription of simian virus 40 DNA is dependent on nuclear domain 10. J. Virol. 74:9694-9700.
102. Shishido-Hara Y, Higuchi K, Ohara S, Duyckaerts C, Hauw JJ, Uchihara T. 2008. Promyelocytic leukemia nuclear bodies provide a scaffold for human polyomavirus JC replication and are disrupted after development of viral inclusions in progressive multifocal leukoencephalopathy. J. Neuropathol Exp. Neurol. 67:299-308.
103. Guo A, Salomoni P, Luo J, Shih A, Zhong S, Gu W, Pandolfi PP. 2000. The function of PML in p53-dependent apoptosis. Nat. Cell Biol. 2:730-736.
104. Schreiner S, Wimmer P, Groitl P, Chen SY, Blanchette P, Branton PE, Dobner T. 2011. Adenovirus type 5 early region 1B 55K oncoproteindependent degradation of cellular factor Daxx is required for efficient transformation of primary rodent cells. J. Virol. 85:8752-8765.
105. Fogal V, Gostissa M, Sandy P, Zacchi P, Sternsdorf T, Jensen K, Pandolfi PP, Will H, Schneider C, Del Sal G. 2000. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J. 19:6185-6195.
106. Lin DY, Huang YS, Jeng JC, Kuo HY, Chang CC, Chao TT, Ho CC, Chen YC, Lin TP, Fang HI, Hung CC, Suen CS, Hwang MJ, Chang KS, Maul GG, Shih HM. 2006. Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. Mol. Cell 24:341-354.